Theragen Etex

At a glance

Theragen Etex filed 25 disclosures in the last 12 months, including 3 insider, 1 5% holder and 1 buyback. The most recent key filing was on Oct 19: CEO's holding fell by 4,601 sh (other change).

Revenue for 2025 was ₩272B, up 8.8% on 2024. Operating margin was 3.8% against 5% a year earlier. Debt was 62% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩138B and operating profit of ₩4.6B.

The 2025 annual report lists 222 employees with an average tenure of 5.6 years and average pay of ₩50.5M, #1433 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩168M each on average. It paid no cash dividend for 2025. 고재훈 and related parties held 13.97% at year end.

From the 2025 annual report

Staff: 222 (118 men, 104 women), of whom 14 on fixed-term contracts. Total pay for the year: ₩11.2B. Directors and auditors: 6, paid ₩1B in total.

No cash dividend was paid for 2025.

Largest shareholder

고재훈 holds 10.14%; with 3 related parties the group holds 13.97% of common shares at year end (from 1.64% at the start of the year).

Auditor: 우리회계법인 · opinion: Unqualified. The report includes an emphasis of matter.

Source: 2025 annual business report (DART). How figures are combined

Financial summary